Clinical Trials at Southeastern Medical Oncology Center-Goldsboro
As of August 2026, 28 paid clinical trials are recruiting at Southeastern Medical Oncology Center-Goldsboro, located at 203 COX BLVD, GOLDSBORO, NC 27534, phone (919) 580-0000 in Goldsboro, North Carolina. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Chronic Lymphocytic Leukemia and Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
28 clinical trials at Southeastern Medical Oncology Center-Goldsboro
·Clear filters·Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Common conditions studied in Goldsboro
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Chronic Lymphocytic Leukemia (3 active studies)
- Malignant Solid Neoplasm (3 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
- Advanced Gastric Adenocarcinoma (2 active studies)
- Advanced Gastroesophageal Junction Adenocarcinoma (2 active studies)
Leading research sponsors in Goldsboro
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- NRG Oncology
- Tempus AI
Frequently asked questions
How many paid clinical trials are currently recruiting in Goldsboro?
There are approximately 32 recruiting clinical trials in Goldsboro, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Goldsboro pay participants?
Most recruiting trials in Goldsboro compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Goldsboro?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Goldsboro?
The most common conditions under active study in Goldsboro include Anatomic Stage II Breast Cancer AJCC v8 (4), Chronic Lymphocytic Leukemia (3), Malignant Solid Neoplasm (3), Advanced Esophageal Adenocarcinoma (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Goldsboro?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Goldsboro on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Goldsboro?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Goldsboro?
Recruiting research sites in Goldsboro include Southeastern Medical Oncology Center-Goldsboro, Godwin Psychiatry, Southeastern Medical Oncology Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Goldsboro right now?
The largest active categories in Goldsboro are Cancer & tumors (28), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Southeastern Medical Oncology Center-Goldsboro?
Southeastern Medical Oncology Center-Goldsboro is located at 203 COX BLVD, GOLDSBORO, NC 27534. Use the Google Maps link in the intro above to get directions.
How do I contact Southeastern Medical Oncology Center-Goldsboro?
You can reach Southeastern Medical Oncology Center-Goldsboro by phone at (919) 580-0000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.